Xenon Pharmaceuticals (XENE) Other Accumulated Expenses (2013 - 2025)
Xenon Pharmaceuticals (XENE) reported Other Accumulated Expenses of $966000.0 for Q4 2025, up 35.29% year-over-year from $714000.0 in Q4 2024, and up 3.32% on a QoQ basis from $935000.0 in Q3 2025.
Xenon Pharmaceuticals (XENE) has 13 years of Other Accumulated Expenses data on file, last reported at $966000.0 in Q4 2025.
- Quarterly Other Accumulated Expenses rose 35.29% year-over-year to $966000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $966000.0 (up 35.29% YoY) and the FY2025 annual result came in at $966000.0, up 35.29% from the prior year.
- Other Accumulated Expenses climbed to $966000.0 in Q4 2025 per XENE's latest filing, from $935000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $1.1 million in Q2 2024 and bottomed at $26000.0 in Q3 2021.
- The 5-year median for Other Accumulated Expenses is $282000.0 (2022), against an average of $418842.1.
- Peak annual rise in Other Accumulated Expenses reached 1106.59% in 2024, while the deepest fall reached 86.13% in 2024.
- Tracing XENE's Other Accumulated Expenses over 5 years: stood at $118000.0 in 2021, then jumped by 188.98% to $341000.0 in 2022, then slumped by 68.62% to $107000.0 in 2023, then soared by 567.29% to $714000.0 in 2024, then soared by 35.29% to $966000.0 in 2025.
- Per Business Quant, the three latest XENE Other Accumulated Expenses figures stand at $966000.0 (Q4 2025), $935000.0 (Q3 2025), and $439000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Xenon Pharmaceuticals | 4.78 Bn | 4.78 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 966,000.00 |
| Sep 30, 2025 | 935,000.00 |
| Jun 30, 2025 | 439,000.00 |
| Mar 31, 2025 | 450,000.00 |
| Dec 31, 2024 | 714,000.00 |
| Sep 30, 2024 | 1.08 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Mar 31, 2024 | 106,000.00 |
| Sep 30, 2023 | 107,000.00 |
| Jun 30, 2023 | 91,000.00 |
| Mar 31, 2023 | 764,000.00 |
| Dec 31, 2022 | 341,000.00 |
| Sep 30, 2022 | 45,000.00 |
| Jun 30, 2022 | 240,000.00 |
| Mar 31, 2022 | 282,000.00 |
| Dec 31, 2021 | 118,000.00 |
| Sep 30, 2021 | 26,000.00 |
| Jun 30, 2021 | 74,000.00 |
| Mar 31, 2021 | 82,000.00 |
| Dec 31, 2020 | 69,000.00 |
| Sep 30, 2020 | 78,000.00 |
| Jun 30, 2020 | 28,000.00 |
| Mar 31, 2020 | 15,000.00 |
| Dec 31, 2019 | 195,000.00 |
| Sep 30, 2019 | 145,000.00 |
| Jun 30, 2019 | 122,000.00 |
| Mar 31, 2019 | 138,000.00 |
| Dec 31, 2018 | 85,000.00 |
| Sep 30, 2018 | 62,000.00 |
| Jun 30, 2018 | 60,000.00 |
| Mar 31, 2018 | 63,000.00 |
| Dec 31, 2017 | 44,000.00 |
| Sep 30, 2017 | 63,000.00 |
| Jun 30, 2017 | 66,000.00 |
| Mar 31, 2017 | 96,000.00 |
| Dec 31, 2016 | 129,000.00 |
| Sep 30, 2016 | 26,000.00 |
| Jun 30, 2016 | 47,000.00 |
| Mar 31, 2016 | 33,000.00 |
| Dec 31, 2015 | 55,000.00 |
| Sep 30, 2015 | 26,000.00 |
| Jun 30, 2015 | 27,000.00 |
| Mar 31, 2015 | 55,000.00 |
| Dec 31, 2014 | 80,000.00 |
| Sep 30, 2014 | 373,000.00 |
| Dec 31, 2013 | 266,000.00 |